Editas Medicine Inc Stock Price, News & Analysis

Editas Medicine (Nasdaq: EDIT) has initiated the enrollment of the first pediatric cohorts in the Phase 1/2 BRILLIANCE clinical trial of EDIT-101, aimed at treating Leber congenital amaurosis 10 (LCA10). This endorsement follows a positive review of safety data from adult cohorts. Concurrently, the adult high-dose cohort is being enrolled, with initial clinical data expected in September. The trial aims to assess safety and efficacy in patients aged 3-17 and includes up to 18 participants.

Editas Medicine, Inc. (Nasdaq: EDIT) announced inducement awards for newly appointed Executive Vice President and Chief Scientific Officer Mark Shearman, Ph.D., and Senior Vice President and Chief Regulatory Officer Chi Li, Ph.D. Each received stock options to purchase shares at $38.53, with vesting over four years. Additionally, they were awarded restricted stock units, also vesting over four years. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are aimed at retaining top executive talent to advance the company's mission in genome editing.

Editas Medicine (Nasdaq: EDIT) has appointed Chi Li, Ph.D., as Chief Regulatory Officer and Mark S. Shearman, Ph.D., as Chief Scientific Officer. Effective immediately, Dr. Li will oversee regulatory affairs, while Dr. Shearman will lead scientific endeavors, enhancing the company’s leadership. With over 30 years of experience, Dr. Shearman previously held roles at AGTC and Merck, while Dr. Li, with over 20 years in drug development, comes from Celularity. This leadership expansion aims to advance Editas' pipeline of gene-editing medicines.

Editas Medicine announced promising preclinical data for EDIT-301, a CRISPR/Cas12a-based therapy for sickle cell disease. The study showed robust fetal hemoglobin (HbF) induction and no off-target editing. The RUBY trial, which is actively recruiting, aims to assess the safety and efficacy of EDIT-301. Manufacturing processes demonstrated successful scale-up production, indicating potential for a durable treatment. The company expects to begin patient dosing by the end of 2021, marking a significant milestone in addressing this serious condition affecting approximately 100,000 individuals in the U.S.

Editas Medicine, Inc. (Nasdaq: EDIT) announced the addition of Dr. Mark S. Shearman as Chief Scientific Officer. The company is advancing its clinical trials, including the BRILLIANCE trial of EDIT-101 for LCA10, with initial clinical data expected by year-end. The RUBY trial for EDIT-301 in sickle cell disease is active and recruiting patients. As of March 31, 2021, Editas reported cash and equivalents of $723 million. The company's net loss for Q1 2021 was $56.7 million. Editas continues to prepare for future developments, including an IND filing for EDIT-301 for beta-thalassemia by year-end.

Editas Medicine, Inc. (Nasdaq: EDIT) has appointed Mark S. Shearman, Ph.D., as Executive Vice President and Chief Scientific Officer, effective June 2021. Dr. Shearman brings over 30 years of experience in drug discovery and development across various therapeutic areas including ophthalmology, immunology, and neurology. He will oversee the drug discovery and research efforts for Editas' pipeline, which focuses on innovative gene editing treatments. Editas aims to develop transformative genomic medicines for serious diseases worldwide.

Editas Medicine (Nasdaq: EDIT) announced three presentations at the ASGCT Annual Meeting from May 11-14, 2021. Key highlights include Heather MacLeod, Ph.D. presenting on CRISPR-based therapies for ocular diseases and preclinical data showcasing a dual AAV CRISPR-Cas9 system targeted at retinitis pigmentosa (RP4). Additionally, a poster on AsCas12a Ultra Nuclease will be presented, emphasizing its role in generating therapeutic cell medicines. These contributions aim to further the understanding and application of genome editing in the clinic.

Editas Medicine announced the acceptance of two scientific abstracts for the ARVO Annual Meeting, showcasing preclinical data on treatments for Usher Syndrome 2A and retinitis pigmentosa 4 (RP4). The findings indicate successful gene editing for USH2A, restoring protein expression and improving photoreceptor morphology in retinal organoids. Additionally, a dual AAV CRISPR-Cas9 system demonstrated clinically relevant editing levels as a potential RP4 therapy. Editas aims to advance these programs towards clinical application, furthering their mission to develop transformative genomic medicines.

Editas Medicine (Nasdaq: EDIT) announced a conference call and webcast on May 5, 2021, at 8:00 a.m. ET to discuss the first quarter results and provide a corporate update. Interested parties can join the call by dialing (844) 348-3801 for toll-free access or (213) 358-0955 for international access. The conference ID is 7587147. The webcast will also be available on Editas Medicine's website. Editas focuses on developing CRISPR-based genomic therapies for serious diseases, aiming to translate genome editing technology into effective treatments.